Arbor Biotech & 4D Molecular Therapeutics Team Up for Gene-Editing Neurological Therapies
Arbor Biotechnologies and 4D Molecular Therapeutics have joined forces to develop innovative gene-editing therapies for neurological disorders. The strategic partnership, announced on January 3, 2024, aims to tackle both rare and common diseases with significant unmet medical needs.
The collaboration will focus on advancing therapies based on adeno-associated viruses (AAVs), which have shown promise in gene editing. Arbor Biotechnologies, known for its expertise in AAV-based therapies, will work alongside 4D Molecular Therapeutics, a leader in gene therapy vector development.
The legal team at WilmerHale played a crucial role in facilitating this partnership. Sarah Hogan and Elese Hanson, both from WilmerHale, advised Arbor Biotechnologies throughout the process.
This strategic alliance between Arbor Biotechnologies and 4D Molecular Therapeutics holds great potential for advancing gene-editing therapies in the central nervous system. The partnership aims to bring much-needed treatments to patients with rare and common neurological diseases.
